General information about HMG 150IU in Belgium
Karma-HMG (Human Menopausal Gonadotropin) is a hormonal substance containing FSH and LH in a 1:1 ratio. In women, Karma-HMG stimulates both the growth and maturation of follicles, it induces an increase estrogen levels and endometrial proliferation. In the male, karmaHMG stimulates spermatogenesis by acting on the production of androgen-binding protein in the seminiferous tubules of Sertoli cells.
Women: karma-HMG and subsequently karma-HCG (Chorionic Gonadotropin Injection) are indicated for the induction of ovulation in amenorrheic or anovulatory patients with regular or irregular cycles. Men: Karma-HMG with concomitant treatment of Karma-HCG (chorionic gonadotropin injection) is indicated for the stimulation of spermatogenesis in men who have primary or secondary hypogonadotrophic hypogonadism.
Treatment should begin with karma-HCG (Chorionic Gonadotropin Injection) 2000 I.U. 2-3 times per week to produce evidence of adequate masculinization. If the response to karma-HCG (chorionic gonadotropin injection) is androgenic only, karma-HMG (1 vial 3 times a week) and karma-HCG (chorionic gonadotropin injection) 2000 I.U. (twice a week) should be administered.
CONTRAINDICATIONS AND WARNINGS:
karma-HMG therapy is excluded when an effective response cannot be obtained, e.g. Ovarian dysgenesis, absence of uterus, premature menopause, tubular occlusion.Men: Patients with elevated endogenous FSH levels indicating primary testicular failure generally do not respond to karma-HMG and karma-HCG (chorionic gonadotropin injection) therapy. Appropriate treatment should first be given for hypothyroidism, adrenocortical deficiency, hyperprolactinemia, or pituitary tumor. An acceptable semen analysis should be available prior to karma-HMG treatment. Adherence to recommended dosage and monitoring schedules will minimize the possibility of ovarian hyperstimulation. Excessive estrogen response to karma-HMG usually does not give significant side effects unless karma-HCG (chorionic gonadotropin injection) is administered to induce ovulation. Hormone tests will detect an excessive estrogen response to karma-HMG and karmaHCG (Chorionic Gonadotropin Injection). In such cases, the administration of karma-HMG should be withheld. The incidence of multiple births following karma-HMG/karma-HCG therapy (chorionic gonadotropin injection) has been reported differently between 10% and 40%. However, the majority of multiple conceptions are twins. Abortion pregnancy losses are higher than in a normal population but comparable to rates in women with other fertility problems. The risks of birth defects are not increased by karma-HMG.
Side effects in Belgium:
In women, local reaction at the injection site, fever and arthralgia have been observed in rare cases. In males, a combined treatment with karma-HMG and karma-HCG (Injectable Chorionic Gonadotropin) can cause gynecomastia.